Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 6/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 7/20 | 0.39 |
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ELANE | P08246 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | F2R | P25116 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4225912 | 0.88 | L3MBTL1 (0.46) | F2RL3L3MBTL1CNR2ACHECNR1 | |
| SCHEMBL4226228 | 0.85 | L3MBTL1 (0.44) | F2RL3L3MBTL1CNR2ACHECNR1 | |
| SCHEMBL3152975 | 0.84 | CNR1 (0.35) | CNR2ACHECNR1MEN1KMT2A | |
| SCHEMBL4226231 | 0.83 | F2RL3 (0.45) | F2RL3L3MBTL1CNR2ACHECNR1 | |
| SCHEMBL13854953 | 0.83 | ELANE (0.47) | F2RL3L3MBTL1CNR2MEN1KMT2A | |
| SCHEMBL4231756 | 0.83 | L3MBTL1 (0.48) | F2RL3L3MBTL1CNR2ACHECNR1 | |
| SCHEMBL3152785 | 0.83 | L3MBTL1 (0.51) | F2RL3L3MBTL1CNR2ACHECNR1 | |
| SCHEMBL13854999 | 0.83 | L3MBTL1 (0.58) | F2RL3L3MBTL1CNR2ACHECNR1 | |
| SCHEMBL4220072 | 0.81 | L3MBTL1 (0.43) | F2RL3L3MBTL1CNR2ACHECNR1 | |
| SCHEMBL3139841 | 0.81 | L3MBTL1 (0.48) | F2RL3L3MBTL1CNR2ACHECNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2155722-B1 | POLYCYCLIC INDAZOLE DERIVATIVES AND THEIR USE AS ERK INHIBITORS FOR THE TREATMENT OF CANCER | MERCK SHARP & DOHME (US) | 2013-08-14 | — | — | EP | disclosed |
| CN-101815711-A | Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer | SCHERING CORP | 2010-08-25 | — | — | CN | disclosed |
| EP-2155722-A1 | POLYCYCLIC INDAZOLE DERIVATIVES AND THEIR USE AS ERK INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| WO-2008153858-A1 | POLYCYCLIC INDAZOLE DERIVATIVES AND THEIR USE AS ERK INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPK10 | F2RL3 3786/4885L3MBTL1 3535/4885CNR2 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.